Recherche avancée

Ernst R. Berndt et Pierre Dubois

n° 702, mars 2012

Cross-country variability in regulatory frameworks, industrial policy, physician/pharmacy autonomy, brand/generic distinctions, and in the practice of medicine contributes to ambiguous interpretations of pharmaceutical cost comparisons. Here we report cross-country comparisons that: (i) focus on 11...

Helmuth Cremer, Philippe De Donder, Dario Maldonado et Pierre Pestieau

vol. 114, n° 1, mars 2012, p. 101–123

mars 2012

Ujjayant Chakravorty, Bertrand Magné et Michel Moreaux

vol. 14, n° 2, mars 2012, p. 349–389

Céline Bonnet et Vincent Réquillart

vol. 47, n° 1, mars 2012, p. 35–41

Hannah Auerbach, Thomas Cocannon, Joshua Cohen, ChiHui Fang, James K. Hammitt, David Kent et Peter Neumann

vol. 21, n° 3, mars 2012, p. 238–251

We assessed how much, if anything, people would pay for a laboratory test that predicted their future disease status. A questionnaire was administered via an internet-based survey to a random sample of adult US respondents. Each respondent answered questions about two different scenarios, each of...

Roberta Dessi et Nina Yin

sous la direction de Douglas J. Cumming, Oxford University Press, chapitre 23, mars 2012

Gilles Saint-Paul, Davide Ticchi et Andrea Vindigni

n° 12-284, 30 mars 2012

Gilles Saint-Paul, Davide Ticchi et Andrea Vindigni

n° 12-284, 30 mars 2012

Stefan Ambec et Claude Crampes

28 mars 2012